What is the mechanism of Zopiclone?

Zopiclone is a non-benzodiazepine hypnotic agent commonly prescribed for the short-term treatment of insomnia. Its mechanism of action primarily involves modulation of the central nervous system to promote sleep. Unlike benzodiazepines, zopiclone is part of the cyclopyrrolone class of drugs and demonstrates unique pharmacological properties.

Zopiclone exerts its hypnotic effects by enhancing the activity of gamma-aminobutyric acid (GABA), the primary inhibitory neurotransmitter in the brain. GABA interacts with GABA_A receptors, which are ligand-gated ion channels that facilitate the influx of chloride ions into neurons. This influx hyperpolarizes the neuronal membrane, making it less likely to fire action potentials, thus exerting a calming effect on the brain's neuronal activity.

 

Researching Zopiclone beyond the basics?

Synapse Hiro LS Researcher, the Synapse AI Insight Engine, is built to accelerate biopharma decisions. Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence. Explore Zopiclone with Hiro LS Researcher →

Although zopiclone is not structurally related to benzodiazepines, it binds to a similar site on the GABA_A receptor complex. Specifically, zopiclone binds to the benzodiazepine recognition site located on the alpha subunit of the GABA_A receptor. This binding increases the affinity of GABA for its receptor, thereby potentiating its inhibitory effects. The enhanced GABAergic activity leads to increased neuronal inhibition, which manifests as sedative and hypnotic effects, aiding in the induction and maintenance of sleep.

Zopiclone has a rapid onset of action, typically within an hour of oral administration, and its effects can last between 6-8 hours. This makes it particularly useful for individuals experiencing difficulty falling asleep or maintaining sleep throughout the night. The drug is metabolized primarily in the liver by the cytochrome P450 enzyme CYP3A4 into its active metabolites, which are then further broken down and excreted via the kidneys.

One of the benefits of zopiclone over traditional benzodiazepines is its relatively favorable side-effect profile. While benzodiazepines are known for causing dependency, tolerance, and significant withdrawal symptoms, zopiclone tends to present these issues to a lesser extent when used appropriately and for short durations. However, it is not devoid of side effects; common adverse reactions include a metallic taste, dry mouth, and in some cases, drowsiness or dizziness the following day.

Despite its efficacy, caution is necessary when prescribing zopiclone. It should be used at the lowest effective dose for the shortest duration necessary to mitigate the risk of dependency and adverse effects. Furthermore, it is contraindicated in individuals with a history of substance abuse, severe hepatic impairment, respiratory insufficiency, and certain psychiatric disorders. 

In summary, zopiclone is an effective hypnotic agent that promotes sleep by enhancing GABAergic inhibition in the brain. Its action at the GABA_A receptor site increases the inhibitory effects of GABA, leading to sedation and the induction of sleep. While it has a better side-effect profile compared to benzodiazepines, it still requires cautious use to avoid potential dependency and other adverse effects.

Continue your Zopiclone research with Synapse Hiro LS Researcher

This article provides an overview. For a broader research view, use Synapse Hiro LS Researcher—the Synapse AI Insight Engine—to search across drugs, targets, indications, clinical trials, literature, organizations, news, deals, and competitor signals. Ask any biopharma research question in natural language.

Questions to explore:

• What is the mechanism of action of Zopiclone, and which targets or pathways are involved?
• What preclinical and clinical evidence supports the proposed mechanism of Zopiclone?
• Which clinical trials are evaluating Zopiclone, and what outcomes have been reported?
• How does Zopiclone compare with other assets targeting the same pathways or indications?

Ask Synapse Hiro LS Researcher →

AI may make mistakes. Check important info.